These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 9723123)

  • 21. Haloperidol-induced catalepsy is absent in dopamine D(2), but maintained in dopamine D(3) receptor knock-out mice.
    Boulay D; Depoortere R; Oblin A; Sanger DJ; Schoemaker H; Perrault G
    Eur J Pharmacol; 2000 Mar; 391(1-2):63-73. PubMed ID: 10720636
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The tiapride-ethanol interaction in animals].
    Spreux-Varoquaux O; Simon P
    Pathol Biol (Paris); 1984 Dec; 32(10):1033-6. PubMed ID: 6542651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protection by the GABAB receptor antagonist, SCH 50911, of gamma-hydroxybutyric acid-induced mortality in mice.
    Carai MA; Colombo G; Gessa GL
    Eur J Pharmacol; 2004 Oct; 503(1-3):77-80. PubMed ID: 15496299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute and subchronic effects of tiapride on isolation-induced aggression in male mice.
    Navarro JF; Manzaneque JM
    Pharmacol Biochem Behav; 1997 Sep; 58(1):255-9. PubMed ID: 9264100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dopamine D1 antagonists potentiate the durations of bar and cling catalepsy and the dorsal immobility response in rats.
    Meyer ME; Cottrell GA; Van Hartesveldt C
    Pharmacol Biochem Behav; 1992 Mar; 41(3):507-10. PubMed ID: 1533938
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The influence of cerebral 5-hydroxytryptamine on catalepsy induced by brain-amine depleting neuroleptics or by cholinomimetics.
    Fuenmayor LD; Vogt M
    Br J Pharmacol; 1979 Oct; 67(2):309-18. PubMed ID: 40649
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties.
    Bardin L; Kleven MS; Barret-Grévoz C; Depoortère R; Newman-Tancredi A
    Neuropsychopharmacology; 2006 Sep; 31(9):1869-79. PubMed ID: 16237379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular and behavioral effects mediated by Gs-coupled adenosine A2a, but not serotonin 5-Ht4 or 5-Ht6 receptors following antipsychotic administration.
    Ward RP; Dorsa DM
    Neuroscience; 1999 Mar; 89(3):927-38. PubMed ID: 10199625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reversal of reserpine-induced catalepsy by selective D1 and D2 dopamine agonists.
    Hubbard CA; Trugman JM
    Mov Disord; 1993 Oct; 8(4):473-8. PubMed ID: 7901761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The potency and efficacy of anticholinergics to inhibit haloperidol-induced catalepsy in rats correlates with their rank order of affinities for the muscarinic receptor subtypes.
    Erosa-Rivero HB; Bata-García JL; Alvarez-Cervera FJ; Heredia-López FJ; Góngora-Alfaro JL
    Neuropharmacology; 2014 Jun; 81():176-87. PubMed ID: 24534110
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy.
    Prinssen EP; Colpaert FC; Koek W
    Eur J Pharmacol; 2002 Oct; 453(2-3):217-21. PubMed ID: 12398907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative study of tiapride and neuroleptics with anti-dopamine activity on convulsive seizure in mice.
    Satoh H; Nakanishi H; Shirakawa K; Kohjimoto Y; Kuwaki T; Ono T; Shibayama F
    Jpn J Pharmacol; 1987 Jan; 43(1):27-32. PubMed ID: 2883332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tiapride. A review of its pharmacology and therapeutic potential in the management of alcohol dependence syndrome.
    Peters DH; Faulds D
    Drugs; 1994 Jun; 47(6):1010-32. PubMed ID: 7521826
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined treatment of ascorbic acid or alpha-tocopherol with dopamine receptor antagonist or nitric oxide synthase inhibitor potentiates cataleptic effect in mice.
    Lazzarini M; Salum C; Del Bel EA
    Psychopharmacology (Berl); 2005 Aug; 181(1):71-9. PubMed ID: 15806417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sensitization versus tolerance to haloperidol-induced catalepsy: multiple determinants.
    Barnes DE; Robinson B; Csernansky JG; Bellows EP
    Pharmacol Biochem Behav; 1990 Aug; 36(4):883-7. PubMed ID: 2217518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The neurosteroid 3 alpha-hydroxy-5 alpha-pregnan-20-one affects dopamine-mediated behavior in rodents.
    Khisti RT; Deshpande LS; Chopde CT
    Psychopharmacology (Berl); 2002 May; 161(2):120-8. PubMed ID: 11981591
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of serotonergic agents on neuroleptic induced catalepsy in rats.
    Rao SG; Hrishikeshavan HJ; Guruswami MN
    Funct Neurol; 1990; 5(4):353-60. PubMed ID: 1982664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Opposite effects of NMDA and AMPA receptor blockade on catalepsy induced by dopamine receptor antagonists.
    Papa SM; Engber TM; Boldry RC; Chase TN
    Eur J Pharmacol; 1993 Mar; 232(2-3):247-53. PubMed ID: 8385618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conditioning to injection procedures and repeated testing increase SCH 23390-induced catalepsy in mice.
    Chinen CC; Frussa-Filho R
    Neuropsychopharmacology; 1999 Nov; 21(5):670-8. PubMed ID: 10516963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Catalepsy produced by long-acting neuroleptics, fluphenazine enanthate and fluphenazine decanoate, in mice.
    Yamada K; Furukawa T
    Pharmacology; 1982; 24(3):147-55. PubMed ID: 7200248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.